Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update-Reference-Cited by-同舟云学术

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

Published:2021-05-12 Issue:6 Volume:35 Page:1631-1642
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hughes Timothy P.^ORCID,Clementino Nelma Cristina D.,Fominykh Mikhail^ORCID,Lipton Jeffrey H.,Turkina Anna G.^ORCID,Moiraghi Elena Beatriz,Nicolini Franck E.,Takahashi Naoto^ORCID,Sacha Tomasz^ORCID,Kim Dong-Wook^ORCID,Fellague-Chebra Rafik,Tiwari Ranjan,Bouard Catherine^ORCID,Mahon Francois-Xavier

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-021-01260-y.pdf

Reference38 articles.

1. Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–93.

2. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

3. Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol. 2016;91:59–66.